Research on cholangitis in 2025 has focused on various aspects, including the diagnostic potential of salivary biomarkers and targeting peroxisome proliferator-activated receptors for primary biliary cholangitis. Studies have also explored connections between primary sclerosing cholangitis and other conditions, such as inflammatory bowel disease and primary Sjogren's syndrome. Additionally, potential treatments like elafibranor have shown promise for primary sclerosing cholangitis.